Use of Growth Hormone Treatment in Skeletal Dysplasia - A Review

Area of Science:

• Pediatric Endocrinology
• Skeletal Dysplasias
• Growth Hormone Therapy

Background:

• Skeletal dysplasias encompass disorders affecting skeletal and cartilaginous tissues, often presenting with short stature.
• Achondroplasia is the most prevalent skeletal dysplasia, frequently managed with growth hormone (GH) therapy in pediatric cases.
• Hypochondroplasia is another skeletal dysplasia where GH treatment has been investigated.

Purpose of the Study:

• To evaluate the efficacy of growth hormone (GH) therapy in children diagnosed with achondroplasia.
• To assess the impact of GH treatment on height velocity in children with hypochondroplasia.
• To explore the potential benefits of GH in other rare skeletal dysplasias.

Main Methods:

• Review of existing studies on growth hormone (GH) administration in pediatric patients with achondroplasia.
• Analysis of data from studies investigating GH treatment effects in children with hypochondroplasia.
• Assessment of growth outcomes, specifically height velocity, following GH therapy.

Main Results:

• Growth hormone (GH) therapy in achondroplasia demonstrated an approximate increase in height velocity of 2-3 cm during the first year of treatment.
• Positive effects of GH were observed in children with hypochondroplasia, with enhanced results noted when treatment commenced during puberty.
• Insufficient data exists for rare skeletal dysplasias to draw conclusions regarding GH efficacy.

Conclusions:

• Growth hormone (GH) therapy is a viable option for improving height velocity in children with achondroplasia.
• Timing of growth hormone (GH) administration, particularly during puberty, may optimize treatment outcomes in hypochondroplasia.
• Further research is needed to determine the role of GH in managing rare skeletal dysplasias.